A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis.

Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs VTP 38543 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Vitae Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2016 Status changed from recruiting to completed.
    • 03 Aug 2016 According to a Vitae Pharmaceuticals media release, the company is on track to report top-line results from this study in the fourth quarter of 2016.
    • 29 Dec 2015 The first patients have been dosed in this trial, according to a Vitae Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top